Your browser doesn't support javascript.
loading
Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified?
Giovannoni, Gavin; Hawkes, Christopher H; Lechner-Scott, Jeannette; Levy, Michael; Yeh, E Ann; Pepper, George; Schmierer, Klaus.
Afiliação
  • Giovannoni G; The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK; Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK. Electronic address: g.giovannoni@qmul.ac.uk.
  • Hawkes CH; The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Lechner-Scott J; The University of Newcastle, Australia.
  • Levy M; Massachusetts General Hospital and Harvard Medical School, Massachusetts, USA.
  • Yeh EA; Department of Paediatrics, Dalla Lana School of Public Health, University of Toronto.
  • Pepper G; Shift.ms, Platform, New Station Street, LS1 4JB, United Kingdom.
  • Schmierer K; The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK; Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Mult Scler Relat Disord ; 87: 105698, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38850685
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Ensaios Clínicos Fase II como Assunto / Esclerose Múltipla Limite: Humans Idioma: En Revista: Mult Scler Relat Disord Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Ensaios Clínicos Fase II como Assunto / Esclerose Múltipla Limite: Humans Idioma: En Revista: Mult Scler Relat Disord Ano de publicação: 2024 Tipo de documento: Article